Mirna Therapeutics Appoints CFO
This article was originally published in Scrip
Mirna Therapeutics, which is developing a broad pipeline of microRNA-based oncology therapeutics, has appointed Alan Fuhrman as chief financial officer. He was most recently the CFO of Ambit Biosciences, where he helped lead the company through its initial public offering and then its sale to Daiichi Sankyo in 2014.
Register for our free email digests: